[Ecabet sodium].
Takahashi
Shin-ichi
S
Third Department of Internal Medicine, Kyorin University School of Medicine.
Tanaka
Akifumi
A
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000658:Amoxicillin / Q000008:administration & dosage; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology; D004224:Diterpenes / Q000008:administration & dosage / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000209:etiology / Q000517:prevention & control; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D014510:Urease / Q000037:antagonists & inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D014510:Urease; D009853:Omeprazole